Company Description: XM Therapeutics is a Brown University spinoff developing tissue repair and regeneration therapies for chronic disorders where an impaired healing response leads to progressive fibrosis (scarring), inflammation, and hypoxia. Applying cutting edge proteomic and 3D cell culture technologies, XM designs injectable human Extracellular Matrix particles (not a cell therapy). The particles engraft in the affected tissue, modulate the dysfunctional matrix to alter cell response, and thereby reduce fibrosis and improve blood flow and organ function. Proof of therapeutic potential has been shown in two animal species and in two organ systems; heart and skin. In both organs, ECM particles had the same effects of reducing scarring and improving healing. The company is pursuing a partnering enabled business model to target multi-billion-dollar conditions starting with chronic wounds and heart failure. Leadership team is in place. Closing seed round and seeking Series A investors.

Goal for Presentation: To gain potential investors and partners and to provide an update on our technology and development milestones.

Additional Comments:

Who referred you to this application?: Glenn Robertelli, Executive Directr, RIBio